Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Published on December 19, 2024

clinical trials; (iii) whether Nurix will be able to fund its research and development activities and achieve its research and development

Continue reading on website
Other news

FactSet Reports Results for First Quarter 2025

December 19, 2024
dealers, banking and advisory firms, and private equity and venture capital firms. Supplementary tables covering organic buy-side and sell-

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

December 19, 2024
Eventide, Dr. Rasbach was a Managing Partner at Pappas Capital, a life science venture capital firm. Earlier in his career, he was an equity